Berger montague securities fraud investigation: apyx medical corporation - apyx medical corp. (nasdaq: apyx); lead plaintiff deadline is august 5, 2022

Philadelphia , july 20, 2022 /prnewswire/ --  berger montague is investigating securities fraud allegations on behalf of investors who purchased the securities apyx medical corporation ("apyx" or the "company") (nasdaq: apyx) between may 12, 2021 and march 11, 2022 (the "class period"). berger montague securities fraud investigation: apyx medical corporation - apyx medical corp.  if you purchased the securities of apyx during the class period, would like to discuss berger montague's investigation, or have questions concerning your rights or interests, please contact attorneys andrew abramowitz at aabramowitz@bm.net or (215) 875-3015, or michael dell'angelo at mdellangelo@bm.net or (215) 875-3080 or visit: https://investigations.bergermontague.com/apyx-medical-/  on march 14, 2022, apyx disclosed that the u.s. food and drug administration (fda) would be posting a medical device safety communication (mdsc) related to the company's advanced energy products.
APYX Ratings Summary
APYX Quant Ranking